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Abstract
Background & aim: The role that H. pylori infection plays in the development of and Barrett's
esophagus (BE) is uncertain. We tested the hypothesis that infection with cagA+ Helicobacter
pylori strains protects against the development of BE.
Methods: We studied 104 consecutive patients, residents in an area with a high prevalence of H.
pylori infection, with BE and 213 sex- and age-matched controls. H. pylori infection and CagA
antibody status were determined by western blot serology.
Results: H. pylori prevalence was higher in patients with BE than in controls (87.5% vs. 74.6%; OR.
2.3; 95% CI: 1.23–4.59). Increasing age was associated with a higher prevalence of H. pylori (p <
0.05). The prevalence of CagA+ H. pylori serology was similar in patients with BE and controls
(64.4% vs. 54.5%; NS). Type I H. pylori infection (CagA+ and VacA+) was similar in patients with
BE and controls (44.2% vs. 41.3%; NS). Logistic regression analysis identified alcohol (O.R. 7.09;
95% CI 2.23–22.51), and H. pylori infection (OR: 2.41; 95%CI: 1.20–4.84) but not CagA+ serology
as independent factors.
Conclusion: Neither H. pylori infection nor H. pylori infection by CagA+ strains reduce the risk
of BE in a population with high prevalence of H. pylori infection.
Background
The incidence of adenocarcinoma of the esophagus has
dramatically increased during the last 2 decades [1-3] and
so has the incidence of Barrett's esophagus (BE), one of
the most important risk factors for esophageal adenocar-
cinoma [4,5]. Despite the fact that BE is a predisposing
factor, only 0.5% of the patients with BE will develop ade-
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nocarcinoma per year [6], meaning that factors that con-
tribute to this development are unknown.
Helicobacter pylori is the major cause of peptic ulcer dis-
ease, and it is also implicated in the pathogenesis of ade-
nocarcinoma of the distal stomach and gastric lymphoma,
especially the mucosa-associated lymphoid tissue-type
lymphoma (MALT lymphoma). The relationship between
corpus gastritis, H. pylori infection, reflux oesophagitis
and Barrett's esophagus is complex and not fully under-
stood. It has been hypothesized that the presence of H.
pylori infection or corpus gastritis may have a protective
effect against GERD because of reduced gastric acid output
[7-10].
An important virulence marker associated with duodenal
ulcer disease is cagA, encoding the cytotoxin-associated
gene protein (CagA) [11]. However, the effect of CagA+
strains in the development of Barrett esophagus might be
in opposite direction to that observed in peptic ulcer dis-
ease. When compared to controls the prevalence of CagA+
H. pylori strains decreased with severity of complications
of GERD, suggesting a protective factor of CagA+ strains in
patients with Barrett's esophagus and its complications
[12-15].
If this hypothesis is correct, H. pylori eradication should
worsen the condition. However to add more confusion to
this scenario, two recent studies have shown that H. pylori
eradication does not influence relapse rates in GERD [16]
and it may be even beneficial on symptomatic relapse in
mild GERD [17]. It has been also suggested that gastritis
and not H. pylori infection is associated with Barrett's
esophagus. In fact, endoscopic diagnosis of reflux
esophagitis or Barrett's esophagus is less common in
patients with corpus gastritis [18]. A number of studies
have examined the relationship between H. pylori infec-
tion and Barrett's esophagus. However, these studies are
limited by small number of patients, the lack of appropri-
ate control population and the low incidence of H. pylori
in the general population.
The aim of this study was to determine whether infection
with CagA+ Helicobacter pylori strains was associated
with a lower risk of Barrett's esophagus development in an
area with a high prevalence of H. pylori infection [13].
Methods
Patients
Since 1999 the Service of Digestive Diseases at the Hospi-
tal Clínico Lozano Blesa is collecting data of all the
patients with endoscopic and pathologic diagnosis of Bar-
rett's esophagus. Such register includes not only patients
diagnosed with BE after that date but also all the available
patients diagnosed since 1972, when the Section of Diges-
tive Endoscopy was created. The Hospital Clínico Lozano
Blesa comprises an area of about 250,000 inhabitants in
the metropolitan area of Zaragoza. In the last two decades
such population has been very stable with a slight incre-
ment. In Spain almost 98% of the people belong to the
National Health Service that provides free Health care to
all its members. The service of Digestive Diseases and the
endoscopy unit are the only gastrointestinal facilities in
that area, thus controlling about 98% of the patients with
gastrointestinal diseases.
For the purpose of this study, control population was
enrolled at the Blood donation facility in the Service of
Hematology at the Hospital Clínico Lozano Blesa. Blood
donors were asked to participate in the study. To be con-
sider a blood donor in Spain, people must be at least 18
years old and no older than 75 and have no major pathol-
ogies. After informed consent was given, a simple health
questionnaire completed prior blood extraction, with spe-
cial attention to current and previous gastrointestinal dis-
eases (mainly GERD related symptoms), previous and
current medication. Patients with clinical symptoms of
gastroesophageal reflux diseases or gastrointestinal symp-
toms as well as patients taking proton pump inhibitors
were excluded from the control group.
Cases were consecutively enrolled from January 2000 to
December 2002. After Barrett's esophagus was histologi-
cally diagnosed, patients were asked to participate in the
study. After informed consent was obtained a complete
health questionnaire was fulfilled including demograph-
ical data, prior and current own and familial medical con-
ditions with special attention to gastrointestinal diseases
and prior and current medications. Exclusion criteria
were: inability of demonstrating Barrett's esophagus in the
pathology examination, patients with prior gastrectomy,
patients with a previous H. pylori eradication, and
patients either with active or past gastric or duodenal ulcer
were also excluded. In order to have a correct age-match-
ing with the control population, patients under 18 years
old and over 80 years old were not included in this study.
Smoking and alcohol intake habits were assessed by per-
sonal questionnaires as well as the socio-economical sta-
tus. The proportion between rural- and urban-living
individuals and socio-cultural status, were similar in both
groups.
The study protocol was approved by the Institutional
Review Board at the University Hospital of Zaragoza and
all patients and controls gave informed consent to the
study, which was conducted in accordance with the Ethi-
cal & Clinical Assays Committee.BMC Gastroenterology 2006, 6:7 http://www.biomedcentral.com/1471-230X/6/7
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Endoscopy protocol
Endoscopy was performed in a fashioned way using either
the Olympus GIF-100 (Olympus, Barcelona, Spain)
video-endoscope or the Fujinon EG-300HR (Fuji, Madrid,
Spain) video-endoscope. After the patient was sedated
upper endoscopy was performed in a standard way and all
the pathology observed was recorded.
The endoscopic grading of esophageal lesions was per-
formed according the Los Angeles Classification [19]. Bar-
rett's esophagus was endoscopically suspected when a
reddish epithelium was seen above the gastroesophageal
junction. Esophageal biopsies were obtained from the
Barrett epithelium in two of the four quadrants and every
two centimeters. Short segment Barrett esophagus was
defined as columnar epithelium not longer than 2 cms
and biopsies were taken every centimeter in such cases.
Special attention was focused in the location of the
squamo-columnar junction and the esophago-gastric
junction with the purpose of identifying endoscopically
the presence of suspicious ectopic mucosa. In order to
avoid misinterpretation of short segment Barrett esopha-
gus with carditis, biopsies were always taken from tongues
of ectopic mucosa penetrating proximally into the
esophagus. The presence or absence of hiatal hernia was
always recorded and forward and retroflexed views were
performed. Any suspicious lesion other than esophageal
was informed and biopsied for study.
Neither rapid urease tests nor gastric histology were part
of the study protocol and they were only collected in case
of concomitant gastric or duodenal lesions.
Histological Analysis
All biopsy specimens were fixed in Hollande's fixative and
stained with H&E for interpretation by a single experi-
Western Blot for H. pylori infection Figure 1
Western Blot for H. pylori infection.
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enced pathologist (JO). Barrett's esophagus was defined as
the presence of specialized columnar epithelium with acid
mucin-containing globet cells in the esophagus. As men-
tioned previously, only patients with confirmed intestinal
metaplasia in the histological analysis were considered as
having Barrett's esophagus.
H. pylori infection and strain analysis
The CagA status was determined in plasma by western
blot with a commercial kit (Bioblot Helicobacter, Biokit
SA. Barcelona, Spain), which has been validated in our
area in previous studies [20-22]. This test determines the
presence/absence of protein bands of 116 kDa (CagA), 89
kDa (VacA), 35 kDa (Urease B), 30 kDa (Urease H), 26.5
kDa (Urease A) and 19.5 kDa (Urease E). Any one band at
116 kDa, 89 kDa or 35 kDa was considered as positive for
H. pylori infection. Any two bands from 30 kDa, 26.5 kDa
or 19.5 kDa were also considered as positive for H. pylori
infection as shown in Figure 1.
Statistical analysis
Based in previous studies [20-22], the sample size was cal-
culated using estimate prevalence of H. pylori of 70% in
controls and a 20% reduction in patients with Barrett's
esophagus (power = 0.80; alpha = 0.05). We analyzed dif-
ferences between groups regarding H. pylori and its strains
status, alcohol and smoking. We first made a bi-variate
analysis for each risk factor separately using the chi-square
test (with the Yates correction in variables with only two
categories) and the Fisher test in tables with expected low
rates. For multivariate analysis we performed a logistic
regression model introducing gender and age to correct
deviations due to theses two factors. We used BMDP soft-
ware (BMDP Statistical Software) for the estimation of the
logistic regression models. Odds ratio (OR) and their 95%
confidence intervals (CI) were used to study the influence
of the different risk factors in the development of Barrett's
esophagus.
Results
Demographic characteristics and endoscopic and 
pathological findings
A total of 104 (82 male, 22 female) patients with Barrett's
esophagus and 213 sex- and age-matched controls were
included in the analysis. Demographic characteristics are
shown in Table 1.
Short segment Barrett' esophagus was found in 67
(64.4%) patients and long segment in 37 (35.6%)
patients. Seventy-five (72.1%) of the patients presented
hiatal hernia.
When dysplasia was analyzed, 11 patients (11%) pre-
sented advanced pathology: high-grade dysplasia in 10
cases and adenocarcinoma in 1 case.
Helicobacter pylori infection
In this population, the prevalence of H. pylori infection in
patients with BE was greater than that found in controls
(87.5% vs. 74.6% respectively; p = 0.013). The prevalence
of CagA+ H. pylori serology was similar in patients with
Barrett's esophagus and controls (64.4% vs. 54.5% respec-
tively; p = 0.118). The presence of both CagA and VacA
antibodys in serum, which defines a more virulent (type
I) strain of H. pylori infection, was also similar in patients
with Barrett's esophagus and controls (44.2% vs. 41.3%
Table 1: Demographics and risk factors
Control (n = 213) Barrett's (n = 104) OR 95% C.I. p
n%n%
Age 53.37 ± 16.01 53.96 ± 16.25 0.995
Gender Male 147 69.0 82 78.8 1.67 0.96–2.91 0.089
Female 66 31.0 22 21.2
M:F ratio 7.9:2.1 7:3
Alcohol No or <80 g/
day
209 98.1 90 86.5 8.13b 2.60–25.37 0.000
>80 g/day 4 1.9 14 13.5
Smoking No 130 61.0 54 51.9
Yes 66 31.0 32 30.8 0.039
Former 17 8.0 18 17.3
H. Pylori Positive 159 74.6 91 87.5 2.38 1.23–4.59 0.013
CagA + Positive 116 54.5 67 64.4 1.51 0.93–2.46 0.118
VacA + Positive 99 46.5 59 56.7 1.51 0.94–2.42 0.111
Type1a Positive 88 41.3 46 44.2 1.13 0.70–1.81 0.710
aType1: CagA+ vacA+
bOR of Barrett's esophagus for >80 grams of alcohol per day vs. <80 gr/dayBMC Gastroenterology 2006, 6:7 http://www.biomedcentral.com/1471-230X/6/7
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respectively; p = 0.710). Table 1 shows both H. pylori
infection and environmental factors in patients with Bar-
rett's esophagus and controls.
We also analysed the prevalence of H. pylori infection
depending on the length of the Barrett's esophagus. No
differences were found between short segment and long
segment Barrett's esophagus regarding H. pylori status,
cagA and VacA serologies as shown in Figure 2.
When combined with other environmental factors, logis-
tic regression analysis identified H. pylori infection (O.R.
2.41; 95% CI 1.20–4.84), and alcohol intake (O.R. 7.09;
95% CI 2.23–22.51) but not or CagA + serology as inde-
pendent factors associated with Barrett's esophagus.
The prevalence of H. pylori infection according to age is
shown in Figure 3. Regardless of the group, increasing age
was associated with a higher prevalence of H. pylori (p <
0.05). We then decided to evaluate the influence of age in
the relationship between Barrett's esophagus and H.
pylori infection including cagA and vacA strains. There is
a trend to a higher prevalence of H. pylori infection in the
age group between 30 and 39 years in patients with Bar-
rett's esophagus compared to controls (p = 0.064). Statis-
tical differences are observed when CagA (p = 0.038) and
VacA (p < 0.001) strains were considered independently.
We then performed logistic regression considering the
interaction between H. pylori and age (stratified as >40
and <40 years). The interaction was not statistically signif-
icant (data not shown) and the logistic regression model
was similar to that obtained in the logistic regression
without age stratification.
We also analyzed the influence of H. pylori infection on
the development of dysplasia. However, the small
H. pylori infection related to age Figure 2
H. pylori infection related to age.
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number of patients with dysplasia did not allow us to
make any statistic analysis.
Discussion
Since the forties of the last century, hospitalization and
mortality rates for H. pylori-associated duodenal ulcers
have decreased. Conversely, those for GERD and esopha-
geal adenocarcinoma, as well as Barrett's esophagus inci-
dence have increased during that same period [23]. Thus,
relationship between H. pylori infection and the develop-
ment of GERD has been subject of study and controversy.
Some studies have shown no causal association while oth-
ers have suggested a possible protective role of H. pylori
infection. The development of corpus gastritis and the vir-
ulence of the strains are different proposed mechanisms
to explain such protection. It has been proposed that
patients with H. pylori-induced gastric atrophy present a
decrease in gastric acidity and subsequently a lower inci-
dence of GERD [7-10]. Moreover, the presence of H.
pylori is also likely to increase the efficacy of PPIs and con-
versely, the eradication of the bacteria decreases the drug
effect. Our study was not designed to evaluate the mecha-
nisms underlying such relationship, and the lack of a pro-
tocol-driven sampling of multiple gastric biopsies in our
study, does not allow us to establish any relationship
between H. pylori infection, gastric atrophy and Barrett's
esophagus. This study was specifically designed to investi-
gate whether gastric infection with CagA+ H. pylori strains
was a protective factor for the development of Barrett's
esophagus. To do this we have used an epidemiological
approach and we found a greater prevalence of H. pylori
infection in patients with Barrett's than that found in con-
trols, and a similar proportion of CagA+ H. pylori strains
in patients and controls.
H. pylori status according to the length of Barrett's esophagus Figure 3
H. pylori status according to the length of Barrett's esophagus.
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Previous studies showed that H. pylori was less prevalent
in patients with gastroesophageal reflux disease (GERD)
than in control subjects [24-26].
Moreover, in the meta-analysis by Gisbert et al [25], the
prevalence of H. pylori infection in patients with Barrett's
esophagus was lower than the incidence in controls (28%
vs. 45%. Odds Ratio: 0.6; 95% CI: 0.48–0.76). On the
other hand, other studies have shown similar results to
ours with higher incidence of H. pylori in patients with
Barrett's esophagus [27].
Our findings strongly support that the presence of H.
pylori is not associated with a decreased incidence of Bar-
rett's esophagus in our population. The question now is
why we have seen such differences in our study compared
to other studies. This is far to be completely understood,
but there are several aspects that may explain the differ-
ences between these studies. The characteristics of the
studied population and the study design could be respon-
sible for some of these differences. Our study is one of the
larger case-control studies aimed to investigating the effect
of H. pylori infection in patients with Barrett's esophagus.
To our knowledge only the study by Lord et al [10] and
the one by Weston et al [28] included more patients with
Barrett's esophagus. However, in the study by Weston the
control group only included GERD patients, who are
obviously very different to our control group. We believe
that GERD patients are not an appropriate control group
in this setting, since both conditions are linked by similar
pathogenic mechanisms. In the Lord study the results
could be different because controls were patients that had
undergone endoscopy meaning they were not asympto-
matic. They also found that H. pylori was more prevalent
in the control group, what could be explained (at least
partially) by the selection of a symptomatic control group,
and consequently with a higher possibility of being
infected with H. pylori.
Choosing the correct control population is a key issue to
asses the relationship between H. pylori and Barrett's
esophagus. It could be argued that blood donors could
also represent a biased population since not everyone is
eligible as a donor. However we think that they represent
an appropriate control population, since they were
healthier and closer to the general population than those
included in other studies, which were patients with GERD
or those undergoing endoscopy due to gastrointestinal
symptoms. Moreover, we excluded those people with
GERD symptoms and those taking PPIs. Although we did
not perform endoscopic procedures in this population, it
must be outlined that there is a high predictive value of
the presence of GERD when heartburn is the dominant or
exclusive symptom [29].
Furthermore, the incidence of H. pylori is very different
from one region to another [26]. In our area this incidence
is very high, as we have shown previously [13]. Such a
high incidence could mask a potential, weak, effect of H.
pylori on the risk of Barrett's esophagus, but, on the other
hand, it could be also expected that a real effect of H.
pylori infection or virulent H. pylori strains on the devel-
opment of Barrett's esophagus could be more easily
shown in areas with high incidence of the infection in the
general population. On the contrary, we found that H.
pylori infection was more frequent in patients with Bar-
rett's esophagus than in our control population, and that
infection with the more virulent strains of H. pylori infec-
tion was not associated with a decreased risk for the devel-
opment of Barrett's esophagus. In fact, the prevalence of
CagA+ strains was similar in H. pylori positive patients
and controls, although a trend toward a greater prevalence
of virulent strains was seen in patients with Barrett's
esophagus. In general, the prevalence of CagA+ strains
obtained in different studies are lower than that found in
our study, however a great variability is observed, with
prevalences ranging from 13.3% to 82% [12,26,30]. In
some way, it is surprising that H. pylori infection was
greater in patients than in controls, indicating that there
was a trend towards an increased frequency of non viru-
lent strains (CagA negative) in controls that in cases. In
any case, all these data indicate that CagA+ H. pylori
strains do not seem to play an important role in this con-
dition among our population and that other factors may
be more important for the development of Barrett's
esophagus. These additional factors could be intrinsic to
the host (i.e. genetic factors) and extrinsic. In fact, it has
been suggested that there may be a genetic predisposition
to the development of reflux in families of patients with
Barrett's esophagus, although a specific genetic defect has
not been found [31,3].
For uncomplicated reflux esophagitis, environmental fac-
tors seem important. Smoking and dietary factors play an
indirect role in the pathophysiology of GERD. Alcohol
can decrease LES pressure and in moderate amounts
impairs the normal acid clearance in supine position. The
effect of smoking is less clear: it can increase the number
of reflux episodes, decrease LES pressure and increase
esophageal acid exposure [34]. We analyzed the influence
of such external factors as alcohol and smoking in this
population and an alcohol intake of more than 80 grams
per day increases the risk of Barrett's esophagus. However,
smoking does not seem to have any influence on the
development of this condition independently of the
amount of cigarettes smoked a day. However, these results
have to be taken with caution since the sample size of the
study was not calculated based on these aspects.BMC Gastroenterology 2006, 6:7 http://www.biomedcentral.com/1471-230X/6/7
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One factor that has been linked to the development and
severity of GERD and Barrett's esophagus is the presence
of a hiatal hernia. We found that 72% of the patients pre-
sented hiatal hernia. These results are similar to those
reported by Arvidan et al [35,36] who found a similar
prevalence of hiatal hernia in patients with Barrett's
esophagus (65%). Thus, Barrett's esophagus occurred
more frequently among subjects with hiatus hernia than
in controls (65% vs. 24%). Moreover, the size of hiatal
hernia increased not only the risk of Barrett's esophagus
but also the risk for adenocarcinoma and severe forms of
GERD [35,36].
One of the potential weakness of the study is the use of
serology for the diagnosis of H. pylori infection. However,
we needed a non-invasive diagnostic test to perform in
controls and serology was the only feasible test to detect
the presence of CagA positive H. pylori strains, since other
non-invasive techniques as urea breath test could not pro-
vide such information. Furthermore, previous studies in
populations from the same area have demonstrated that
serology had an excellent correlation with the results
obtained by either the urea breath test or the rapid urease
test [20,21], and a good method to asses the presence or
absence of CagA and VacA antibodys. Moreover, the con-
trol group was enrolled from the blood donation facility
making a blood-based test very convenient because it can
be performed very easily in healthy controls in which an
endoscopic procedure would be hardly justifiable and
perhaps unethical. We did not take any biopsy to asses
Helicobacter pylori status and it could be argued that sero-
logical methods to asses the presence and strain of Helico-
bacter pylori, is not sufficient to not consider gastric
histology a valuable tool for strain genotyping or evalua-
tion of extension/severity of gastritis. However, the biopsy
protocol for patients with Barrett's esophagus in our hos-
pital does not include routine gastric sampling for Helico-
bacter pylori investigation if no other lesion is found
during endoscopy. Furthermore, performing endoscopies
in controls to assess Helicobacter pylori status through
biopsies would have been difficult to explain and could
be even considered unethical.
The exclusion of BE cases with active or past peptic ulcer
could be considered a selection bias towards patients with
less virulent strains compared to controls. However, most
of the patients with peptic ulcer history in our region are
infected with Helicobacter pylori and including such cases
would have represented a higher selection bias. Moreover,
excluding peptic ulcer patients reduces the chance that
individuals in the control group had a better chance to be
colonized by cagA-negative Helicobacter pylori strains com-
pared to individuals in the study group.
Another potential weakness of our study is the diagnosis
of Barrett's esophagus. We have used endoscopic and
pathologic criteria. However, from a histological point of
view, it is impossible to distinguish between intestinal
metaplasia in the esophagus from that at the gastro-
esophageal junction (GEJ). This is particularly important
in patients diagnosed with short segment Barrett's esopha-
gus. Some authors have used specific staining cytokeratin
markers CK7 and CK20 to differentiate the two types [37].
Although we tried to avoid biopsies at the GEJ there is not
a way to unequivocally exclude patients with intestinal
metaplasia of the GEJ.
If our study would have included many cases misdiag-
nosed as SSLB we should have observed a lower preva-
lence of H. pylori infection in the LSBE group compared
to the SSBE, similar to what we observed in cases versus
controls. However, we did not find such differences sug-
gesting that the diagnosis of Barrett' esophagus was correct
or, at least, that if we included few misdiagnosed patients,
they did not have a major influence on the results.
In conclusion, this study demonstrates that, neither H.
pylori infection nor H. pylori infection by cagA+ strains
decrease the risk of Barrett's esophagus in a population
with high prevalence of H. pylori infection. Further
research is needed to identify other factors like environ-
mental or genetics that may play a role in Barrett's devel-
opment into cancer.
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